Autoimmune Biologics Deal Benchmarks
Market Analysis
Autoimmune biologics remain one of the most actively licensed categories in biopharma, driven by large patient populations and proven commercial models. Phase 2 autoimmune biologic deals achieve a median total deal value of $3.0B, with upfront payments from $304M to $835M. The chronic treatment paradigm and multi-indication expansion potential create highly valuable licensing opportunities.
Milestone structures for autoimmune biologics balance development ($490M), regulatory ($858M), and commercial milestones ($1.1B). The 19/81 upfront/milestone structure reflects the de-risked Phase 2 stage and the established regulatory pathway for autoimmune indications.
Royalty rates range from 14% to 23.4% base, with escalation to 27.4% on blockbuster sales. Differentiation versus anti-TNF biologics, novel mechanisms (anti-TL1A, anti-IL-23, BCMA-targeting), and subcutaneous formulations drive premium royalty tiers. Multi-indication potential across RA, lupus, and IBD significantly enhances total deal economics.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What is the average deal value for autoimmune biologic licensing?
How does multi-indication potential affect autoimmune deal terms?
What autoimmune targets are commanding the highest deal premiums in 2026?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.